96 related articles for article (PubMed ID: 28554216)
1. Nanoparticulation improves bioavailability of Erlotinib.
Yang KM; Shin IC; Park JW; Kim KS; Kim DK; Park K; Kim K
Drug Dev Ind Pharm; 2017 Sep; 43(9):1557-1565. PubMed ID: 28554216
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC
Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs.
Choi J; Ko E; Chung HK; Lee JH; Ju EJ; Lim HK; Park I; Kim KS; Lee JH; Son WC; Lee JS; Jung J; Jeong SY; Song SY; Choi EK
Int J Nanomedicine; 2015; 10():6121-32. PubMed ID: 26457052
[TBL] [Abstract][Full Text] [Related]
4. A nanosystem for water-insoluble drugs prepared by a new technology, nanoparticulation using a solid lipid and supercritical fluid.
Park JW; Yun JM; Lee ES; Youn YS; Kim KS; Oh YT; Oh KT
Arch Pharm Res; 2013 Nov; 36(11):1369-76. PubMed ID: 23780798
[TBL] [Abstract][Full Text] [Related]
5. HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.
Shen Y; Li W
Drug Des Devel Ther; 2018; 12():2285-2292. PubMed ID: 30087553
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
[TBL] [Abstract][Full Text] [Related]
7. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
Zhou X; Tao H; Shi KH
Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
[TBL] [Abstract][Full Text] [Related]
8. Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach.
Park SY; Kang Z; Thapa P; Jin YS; Park JW; Lim HJ; Lee JY; Lee SW; Seo MH; Kim MS; Jeong SH
Int J Pharm; 2019 Jul; 566():229-238. PubMed ID: 31136778
[TBL] [Abstract][Full Text] [Related]
9. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
Madsen CM; Boyd B; Rades T; Müllertz A
Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
[TBL] [Abstract][Full Text] [Related]
10. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
[TBL] [Abstract][Full Text] [Related]
11. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies.
Parveen R; Ahmad FJ; Iqbal Z; Samim M; Ahmad S
Drug Dev Ind Pharm; 2014 Sep; 40(9):1206-12. PubMed ID: 23826860
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
13. Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.
Momin MM; Zaheer Z; Zainuddin R; Sangshetti JN
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1064-1075. PubMed ID: 28758795
[TBL] [Abstract][Full Text] [Related]
14. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
[TBL] [Abstract][Full Text] [Related]
16. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
[TBL] [Abstract][Full Text] [Related]
17. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
18. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
Franek F; Holm P; Larsen F; Steffansen B
Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
[TBL] [Abstract][Full Text] [Related]
19. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
20. Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state.
Miao Y; Sun J; Chen G; Lili R; Ouyang P
Drug Dev Ind Pharm; 2016 Aug; 42(8):1234-40. PubMed ID: 26582334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
